COMPANY PROFILE

Empyrean Neuroscience

Using genetic engineering to treat severe neuropsychiatric and neurologic illnesses in a way that will revolutionize healthcare

New York City, United StatesFounded 2019Biotech & Life Sciences

Valuation $100–250M Last recorded · 2022

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Empyrean Neuroscience

Empyrean.bio is a pioneering biotechnology company focused on the genetic engineering of fungi and plants to develop neuroactive therapeutics. The company addresses the needs of patients suffering from debilitating neuropsychiatric and neurologic disorders such as depression, post-traumatic stress disorder (PTSD), substance abuse disorders, and chronic pain. By leveraging proprietary capabilities in fungi and plant genetics, bioinformatics, transformation, and regeneration, Empyrean.bio can upregulate and downregulate specific genes to modify the production of neuroactive compounds. This innovative approach allows for the creation of highly targeted treatments that can potentially transform the landscape of mental health and neurological care.

Empyrean.bio operates in the biotechnology and pharmaceutical markets, serving healthcare providers, research institutions, and patients. The company's business model revolves around the development and commercialization of its proprietary neuroactive compounds. Revenue is generated through partnerships, licensing agreements, and direct sales of its therapeutic products.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2019
Headquarters: New York City, United States
Employees: 8
Open positions: None listed
Dealroom signal: 57.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Addiction, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Oct 2022	$22M	$88M	Spore Partners	↗

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Empyrean Neuroscience website traffic

Latest recorded traffic for Empyrean Neuroscience is 250 monthly website visits, up 108.3% over the last three months. Empyrean Neuroscience's team grew 0% over the past year.

Latest monthly visits250 3-month web change+108.3% 1-year team growth0%

Monthly website visitsDec 2022–Mar 2024

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CLClexBioA biotech company creating breakthrough solutions for tissue engineering and single-cell techniques by combining advanced microfluidics with proprietary hydrogel technology	Oslo, Norway	Operational	9	$2.3M	$4.8M
LALarondePioneering a completely novel translatable RNA platform - Endless RNA (eRNA)	Cambridge, United States	Operational
IAImmunito AIAn in-silico Antibody Discovery company which uses Artificial Intelligence to give the fastest and most accurate solutions	Bengaluru, India	Operational
KIKimialysDeveloper of an analytical device intended to offer products based on innovative surface chemistry in the field of biosensors	Paris, France	Operational
SISideROSFocused on accelerated development of innovative small molecules targeting tumour cells metabolism in high-risk cancers	Paris, France	Closed
KTKintsugi TherapeuticsDevelopment of ER stress inhibitors for the treatment of metabolic diseases	Barcelona, Spain	Operational
ASASYLIACompanion Diagnostics For Immunotherapy \| Asylia Diagnostics	Beerse, Belgium	Operational
ANAntegenesGenetic tests for personalized cancer risk prevention	Tartu, Estonia	Operational